US OptionsDetailed Quotes

LNN241220C175000

Watchlist

0.00
0.000.00%

15min DelayClose Nov 19 09:30 ET

0.00High0.00Low

Lindsay Stock Discussion

Moomoo AI

Mar 9 07:52

Lindsay's rising ROCE and capital employed are encouraging, indicating successful business reinvestment and higher returns. These promising trends may be underappreciated by investors, potentially making the stock a solid long-term investment.

Returns On Capital Are Showing Encouraging Signs At Lindsay (NYSE:LNN)

Moomoo AI

Jan 4 10:58

Lindsay Corporation's in-line P/E ratio omits its weaker earnings forecast. A P/E fall to match growth outlook may upset investors. Balance sheet risks cause unease.

Lindsay Corporation's (NYSE:LNN) Popularity With Investors Is Under Threat From Overpricing

Moomoo AI

Nov 10, 2023 04:25

Given Lindsay's rapid earnings growth, its reinvestment of profits into business expansion, along with a conservative payout ratio, the company appears to have strong prospects for future growth and a reduced risk of future dividend cuts.

There's A Lot To Like About Lindsay's (NYSE:LNN) Upcoming US$0.35 Dividend

Moomoo AI

Oct 18, 2023 06:42

The positive trends in Lindsay's ROCE and capital employment are encouraging signs for its potential as an investment. The current shareholder return of 34% over the past five years suggests the market may not yet fully recognize Lindsay's promising fundamentals.

Lindsay (NYSE:LNN) Shareholders Will Want The ROCE Trajectory To Continue

Moomoo Breakfast US

Jul 1, 2022 07:35

Columns Today's pre-market stock movers: KSS, NIO, MU, LULU and more

Gainers:
• $Cytokinetics (CYTK.US)$ +8.7% (prices offering of of $450.0 mln of 3.50% convertible senior notes due 2027)
• $XPeng (XPEV.US)$ +3.4% (June deliveries)
• $NIO Inc (NIO.US)$ +2.9% (June deliveries)
• $Bitfarms (BITF.US)$ +2.7% (provides June 2022 production and mining operations update)
• $Accolade (ACCD.US)$ +2.7% (In reaction to earnings/guidance)
• $BioCryst Pharmaceuticals (BCRX.US)$ +2.6% (presents new data demonstrating...

No comment yet